Results from the phase 3 CLL17 trial (NCT04608318) are helping clarify the ongoing debate over continuous vs fixed-duration therapy in frontline chronic lymphocytic leukemia (CLL) ...

A $27.2 million one-time non-cash gain was recorded in Q4 2025 following the final sale of Erivedge rights to Oberland.

Curis, Inc. (NASDAQ:CRIS) Q4 2025 Earnings Call Transcript March 19, 2026 Curis, Inc. misses on earnings expectations. Reported EPS is $-0.5 EPS, expectations were $-0.436. Operator: Good afternoon, ...

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today reported its business ...

James Dentzer, President and CEO, stated that "we continue to make steady progress in our TakeAim Lymphoma study in primary CNS lymphoma, one of the most rare and most difficult to treat of the NHL ...

Thank you, and welcome to Curis' Fourth Quarter 2025 Business Update Call. Before we begin, I'd like to encourage ...

During a live event, Catherine Coombs, MD and participants debate frontline CLL BTK inhibitors: who benefits from continuous therapy, acalabrutinib vs zanubrutinib nuances, and pirtobrutinib's future ...

Across treatment classes, CH associated with increased therapy-related cytopenias, particularly neutropenia, and DNMT3A/TET2 ...

The awareness of women in terms of health is gaining significance in contemporary medical care, particularly in matters of blood cancers such as Chronic Lymphocytic Leukemia The post Women’s Health ...

CLL," Cleveland Clinic hematologist/oncologist Allison Winter, MD, and host John Mangels explore how clinicians can communicate effectively and empathetically with patients navigating a chronic ...

BTK inhibitor monotherapy is foundational across several B-cell malignancies, with newer, more selective agents designed to preserve efficacy while improving tolerability relative to first-in-class ...